Articles · Biology

Progesterone Decline in Perimenopause

Progesterone falls before estrogen, and its brain effects explain the earliest symptoms.

8 min read · Published May 30, 2026 · Updated September 9, 2026

Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.

Progesterone Decline in Perimenopause

Most talk about menopausal hormones is about estrogen. Hot flashes, vaginal dryness, the case for HRT: all framed around estrogen. Progesterone gets mentioned mainly as the hormone added to protect the womb from the effect of estrogen on its lining.

That framing misses most of what progesterone does. It has direct effects on the brain, on sleep, on mood stability, on anxiety, and on the heart and blood vessels. These effects are separate from estrogen, and many women lose them before any estrogen-related symptoms appear.

Progesterone Falls First

During the reproductive years, progesterone is made mainly in the corpus luteum, the temporary gland that forms in the ovary after ovulation. No ovulation, no corpus luteum. No corpus luteum, and progesterone in the second half of the cycle drops close to zero.

Progesterone decline is tied to ovulation, not to estrogen production. In early perimenopause, estrogen can still be normal, sometimes even high, as the pituitary pushes the follicles harder in response to falling ovarian responsiveness. But ovulation becomes irregular. Some cycles have no ovulation. In those cycles, progesterone does not rise in the second half.

So many women enter a phase of relative progesterone shortfall while estrogen is still adequate or high.[1] Non-clinical writing often calls this estrogen dominance. The more precise term is progesterone insufficiency relative to estrogen. Either way, the imbalance starts with progesterone.

Progesterone’s Effect on the Brain

Progesterone does not stay in the bloodstream unchanged. In the brain, an enzyme (5-alpha reductase) converts it into a molecule called allopregnanolone. Allopregnanolone is a potent positive modulator of GABA-A receptors, the main calming receptors in the nervous system.[2]

GABA is the main calming signal. GABA-A receptors carry the anti-anxiety and sedative effects of several drug classes, including benzodiazepines, barbiturates, and anaesthetics. Allopregnanolone acts at the same receptors through a different binding site.

When progesterone and its conversion to allopregnanolone are adequate, there is a steady calming influence on the nervous system. There is a chemical basis for calm. When progesterone falls, that basis is removed: nerve cells become more excitable, the threshold for anxiety drops, and threat responses are less well dampened.

The GABA mechanism for allopregnanolone is one of the most clearly worked-out hormonal effects on the brain in the neuroscience literature.[2] It directly explains why early perimenopause, when estrogen may still be adequate but progesterone is falling, often shows up as anxiety, trouble sleeping, and mood swings rather than hot flashes.

Progesterone and Sleep

Progesterone promotes sleep in two ways: through the allopregnanolone pathway it increases GABA-driven sedation and reduces the time it takes to fall asleep, and through a direct effect on the breathing control centres in the brainstem it increases breathing drive during sleep.[3] The breathing mechanism has clinical consequences: progesterone is a respiratory stimulant, and its decline after menopause is one reason sleep apnea becomes more common in postmenopausal women. Estrogen also supports upper airway muscle tone, and its decline adds to the risk, but these are separate mechanisms.[4]

For perimenopausal women with insomnia (especially trouble falling asleep, or a busy mind at bedtime), symptoms often appear at a stage when estrogen is still present but progesterone has become on-and-off or low. This is not estrogen-related insomnia driven by night sweats. It is GABA withdrawal from a chemical basis that used to be reliable.

Progesterone and Mood

The relationship between progesterone, its metabolites, and mood goes both ways and depends on context. Adequate progesterone and allopregnanolone supports mood stability and reduces anxiety in most women. But some research on PMDD (premenstrual dysphoric disorder) has found that a subset of women has a paradoxical sensitivity to allopregnanolone, getting more anxiety and low mood from normal luteal-phase progesterone shifts rather than benefit.[5] This appears to be the same group that has worse mood on certain progestogen-containing HRT regimens.

The distinction matters clinically. Most perimenopausal women have mood swings from progesterone shortfall and benefit from adequate progesterone or micronised progesterone. A smaller group has allopregnanolone sensitivity and may have worse mood on certain progestogen forms. When mood symptoms on HRT track specifically with the progestogen phase, the form, not the hormone class, is the likely issue.

Synthetic Progestogens Are Not Progesterone

One of the most consequential misunderstandings in HRT is treating synthetic progestogens as the same as progesterone. They are not.

Synthetic progestogens (norethisterone, medroxyprogesterone acetate, levonorgestrel, and others) were developed because natural progesterone is poorly absorbed by mouth and broken down too fast to work as a once-daily tablet. Progestogens solve these problems through changes to the molecule.

The changes that improve stability also change how the molecule binds receptors. Different progestogens have varying degrees of androgenic, anti-androgenic, glucocorticoid, and anti-mineralocorticoid activity depending on structure.[6] Norethisterone, widely prescribed in the UK, has androgenic activity. MPA, used heavily in the US and the subject of the Women’s Health Initiative hormone arm, has distinct effects on breast tissue and heart markers compared with natural progesterone.

Micronised progesterone (Utrogestan in the UK and Europe; Prometrium in the US) uses natural progesterone processed into fine particles to improve absorption. It converts to allopregnanolone; synthetic progestogens do not. It lacks the androgenic or glucocorticoid activity of many progestogens. Its breast cancer risk profile appears more favourable than synthetic progestogens, based on observational data from the E3N cohort study.[7]

For mood, sleep, and anxiety, micronised progesterone is almost always better tolerated than synthetic progestogens. For women who have had significant mood symptoms on progestogen-containing HRT, the first question is which progestogen they were taking, and the first thing to try is switching to micronised progesterone before concluding that all progestogens cause problems.

Using Progesterone Without Estrogen

There is some evidence that oral progesterone can be used alone in perimenopause, without estrogen, for women who want relief from anxiety and sleep symptoms linked to early progesterone decline. A small randomised trial by Hitchcock and Prior (2012) found that oral progesterone 300 mg at bedtime reduced hot flash frequency and improved sleep in postmenopausal women, though the study was small.[8] Bedtime dosing makes use of the sedative GABA effect.

This is not a standard first-line treatment, and progesterone alone does not protect the womb without estrogen. But it is a clinical option worth discussing with a menopause-informed prescriber, especially for women in early perimenopause whose main symptoms are sleep and anxiety rather than hot flashes.

Reading Early Perimenopausal Symptoms

Understanding the timeline of progesterone decline relative to estrogen has practical implications for how symptoms are read.

Trouble sleeping (especially trouble falling asleep), more anxiety, low-level restlessness, and worse PMS in the second half of cycles: this cluster fits on-and-off progesterone shortfall from cycles with no ovulation or a short luteal phase. Estrogen-driven symptoms (hot flashes, night sweats, vaginal dryness) may not be present yet. This phase can last several years before the more recognisable hot flashes appear. Having words for it makes it easier to describe accurately to a prescriber, opens the conversation about progesterone-specific options, and avoids the years of misattribution that happen when these symptoms are labelled as an anxiety disorder or poor sleep habits rather than hormonally driven.

When to Seek Clinical Review

Symptoms that fit progesterone shortfall (ongoing insomnia, more anxiety, mood swings, or worse premenstrual symptoms in the second half of cycles) are worth raising with a menopause-informed clinician rather than just monitoring. A prescriber familiar with perimenopause can assess the hormonal picture, rule out other causes, and discuss whether micronised progesterone or a change in progestogen form fits. This is especially relevant if symptoms are affecting daily life, if they have lasted across several cycles, or if a previous HRT regimen caused mood side effects that were never looked into beyond stopping the prescription.


References

[1] Prior, J. C. (1998). Perimenopause: The complex endocrinology of the menopausal transition. Endocrine Reviews, 19(4), 397–428. https://doi.org/10.1210/edrv.19.4.0341

[2] Lambert, J. J., Belelli, D., Peden, D. R., Vardy, A. W., Peters, J. A. (2003). Neurosteroid modulation of GABA-A receptors. Progress in Neurobiology, 71(1), 67–80. https://doi.org/10.1016/j.pneurobio.2003.09.001

[3] Driver, H. S., McLean, H., Kumar, D. V., Bhargava, R., McKibbon, A. E., Shapiro, C. M. (1996). The influence of the menstrual cycle on upper airway resistance and breathing during sleep. Sleep, 19(Suppl 2), S132–S134.

[4] Popovic, R. M., White, D. P. (1998). Upper airway muscle activity in normal women: Influence of hormonal status. Journal of Applied Physiology, 84(3), 1055–1062. https://doi.org/10.1152/jappl.1998.84.3.1055

[5] Backstrom, T., Andreen, L., Birzniece, V., et al. (2003). The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs, 17(5), 325–342. https://doi.org/10.2165/00023210-200317050-00003

[6] Schindler, A. E., Campagnoli, C., Druckmann, R., et al. (2003). Classification and pharmacology of progestins. Maturitas, 46(Suppl 1), S7–S16. https://doi.org/10.1016/j.maturitas.2003.09.014

[7] Fournier, A., Berrino, F., Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103–111. https://doi.org/10.1007/s10549-007-9523-x

[8] Hitchcock, C. L., Prior, J. C. (2012). Oral micronized progesterone for vasomotor symptoms: A placebo-controlled randomized trial in healthy postmenopausal women. Menopause, 19(8), 886–893. https://doi.org/10.1097/gme.0b013e318247f07a

Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.